Targeted Oncology presents Investigator Perspectives, a video series featuring key opinion leaders discussing how to approach and manage patients with different tumor types.
Advances in Myelofibrosis Treatment
Read More
Understanding Radioactive Iodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC)
Metastatic Renal Cell Carcinoma: Updates to CheckMate 9ER and COSMIC-313 Trial Data
Treating Radioactive Iodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC) with Lenvatinib
Immune Checkpoint Inhibitor Metastatic NSCLC: Combination Strategies
Potential Role of Elacestrant for the Treatment of Metastatic ER+/HER2- Breast Cancer
The Evolving Treatment Landscape for Myelofibrosis
The Current Field of Graft Versus Host Disease
Use of Venetoclax in Newly Diagnosed Acute Myeloid Leukemia (AML)
The Phase 2 REFINE Trial: Ruxolitinib Plus Navitoclax for Myelofibrosis
Metastatic Castration-Resistant Prostate Cancer: Updates to VISION Trial Data
The Phase 3 CLEAR Trial: Lenvatinib Plus Pembrolizumab or Everolimus for Advanced RCC
Endometrial Carcinoma Treatment Advances
Novel Immune Checkpoint Inhibitors in Advanced Cervix Cancer
Advanced/Metastatic Cholangiocarcinoma Treatment Landscape
The CLEAR Trial: Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Transarterial Yttrium-90 Radioembolization with Chemotherapy for the Treatment of Colorectal Liver Metastasis: The EPOCH Study
Prostate Cancer: The VISION Trial
Metastatic Castrate-Resistant Prostate Cancer Treatment: Updates on Use of Darolutamide
Transplant Ineligible Multiple Myeloma: Updates to the MAIA Study
Acute Myeloid Leukemia: Advances in Initial Therapy
Advances in the Treatment of Myelodysplastic Syndrome: Targeting CD47
Metastatic Colorectal Cancer: Advances in Non-Chemotherapy Treatment Options
AMEERA-1: Phase 1-2 Study of Amcenestrant, An Oral Selective Estrogen Receptor Degrader, With Palbociclib in Postmenopausal Women With ER+ HER2- Metastatic Breast Cancer
Radioligand Therapy 177Lu-PSMA-617 in Patients With Progressive PSMA-positive mCRPC
Phase 3 IMbrave150 Trial in Patients with Unresectable Hepatocellular Carcinoma: 2021 Update
Ruxolitinib for Steroid-Refractory GVHD: The REACH Trials
Phase 3 REFLECT Trial in Patients with Unresectable Hepatocellular Carcinoma
Radioligand Therapy 177Lu-PSMA-617 in Progressive PSMA-positive mCRPC
The Phase 3 CLEAR Trial: Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma